Insights

Innovative Research Focus MIT Koch Institute's emphasis on interdisciplinary approaches to cancer research, including nanotechnology, immunotherapy, and precision medicine, presents opportunities for collaboration with biotech and pharmaceutical companies seeking cutting-edge research tools and partnerships.

Emerging Technology Development The institute’s active development of AI models for CAD software, wearable skin monitoring platforms, and advanced polymer films indicates potential for selling advanced materials, AI integration services, and innovative diagnostic technology to industry players.

Strategic Partnerships Collaborations with global brands like Amorepacific for skincare innovations showcase capability to partner with consumer health and wellness brands seeking new digital health solutions and personalized healthcare products.

Research Funding and Growth With a significant funding level of $6 million and revenue between $10 million and $25 million, the institute is positioned for growth, opening avenues for securing grants, joint ventures, and technology licensing deals from medical device, biotech, and pharmaceutical sectors.

Industry Engagement Active participation in events like CES and collaborations with external entities highlight opportunities to showcase and commercialize innovative research outputs, attracting industry interest in licensing, joint ventures, or product development collaborations.

MIT Koch Institute for Integrative Cancer Research Tech Stack

MIT Koch Institute for Integrative Cancer Research uses 8 technology products and services including Adobe, Tableau, IBM Cognos Business Intelligence, and more. Explore MIT Koch Institute for Integrative Cancer Research's tech stack below.

Adobe

Audio, Video, Graphics

Tableau

Business Intelligence

IBM Cognos Business Intelligence

Business Intelligence

MySQL

Database

Okta

Identity Verification

Modernizr

Javascript Libraries

Nginx

Web Servers

Magnific Popup

Web Tools And Plugins

MIT Koch Institute for Integrative Cancer Research Email Formats	Example	Percentage
FLast@mit.edu	JDoe@mit.edu	79%
Last@mit.edu	Doe@mit.edu	8%
FirstL@mit.edu	JohnD@mit.edu	7%
First.Last@mit.edu	John.Doe@mit.edu	6%

MIT Koch Institute for Integrative Cancer Research Email Formats

Example

Percentage

FLast@mit.edu

JDoe@mit.edu

79%

Last@mit.edu

Doe@mit.edu

FirstL@mit.edu

JohnD@mit.edu

First.Last@mit.edu

John.Doe@mit.edu

Frequently Asked Questions

Where is MIT Koch Institute for Integrative Cancer Research's headquarters located?

MIT Koch Institute for Integrative Cancer Research's main headquarters is located at 500 Main Street, Building 76 Cambridge, Massachusetts 02139, US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is MIT Koch Institute for Integrative Cancer Research's official website and social media links?

MIT Koch Institute for Integrative Cancer Research's official website is mit.edu and has social profiles on LinkedIn Crunchbase.

What is MIT Koch Institute for Integrative Cancer Research's NAICS code?

MIT Koch Institute for Integrative Cancer Research's NAICS code is 5417 - Scientific Research and Development Services.

How many employees does MIT Koch Institute for Integrative Cancer Research have currently?

As of October 2025, MIT Koch Institute for Integrative Cancer Research has approximately 501 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Founder And President: C. K.Senior Vice President: C. T. C.Associate Director: A. K.. Explore MIT Koch Institute for Integrative Cancer Research's employee directory with LeadIQ.

What industry does MIT Koch Institute for Integrative Cancer Research belong to?

MIT Koch Institute for Integrative Cancer Research operates in the Research Services industry.

What technology does MIT Koch Institute for Integrative Cancer Research use?

MIT Koch Institute for Integrative Cancer Research's tech stack includes AdobeTableauIBM Cognos Business IntelligenceMySQLOktaModernizrNginxMagnific Popup.

What is MIT Koch Institute for Integrative Cancer Research's email format?

MIT Koch Institute for Integrative Cancer Research's email format typically follows the pattern of FLast@mit.edu. Find more MIT Koch Institute for Integrative Cancer Research email formats with LeadIQ.

How much funding has MIT Koch Institute for Integrative Cancer Research raised to date?

As of October 2025, MIT Koch Institute for Integrative Cancer Research has raised $6M in funding. The last funding round occurred on Apr 11, 2022 for $6M.

When was MIT Koch Institute for Integrative Cancer Research founded?

MIT Koch Institute for Integrative Cancer Research was founded in 2008.

MIT Koch Institute for Integrative Cancer Research

Research ServicesUnited States501-1000 Employees

The Koch Institute for Integrative Cancer Research, a National Cancer Institute-designated Basic Cancer Research Center, is the hub of cancer research on the MIT campus. Bringing together biologists, chemists, engineers, computer scientists, clinicians, and others in a state-of-the-art facility, the Koch Institute oﬀers fresh perspectives and interdisciplinary approaches to advancing the ﬁght against cancer. Koch Institute investigators are focused on ﬁve research areas that are believed to be critical for rapid progress toward controlling cancer: nanotechnology-based cancer therapeutics, detection and monitoring, metastasis, precision cancer medicine, and cancer immunology and immunotherapy. Working within the vibrant MIT research community and with external collaborators, including NCI-designated clinical cancer centers and biotech/pharma partners, the Koch Institute is dedicated to developing novel insights into cancer, as well as new tools and technologies to better detect, treat, and prevent the disease.

Insights

Similar companies to MIT Koch Institute for Integrative Cancer Research

St. Jude Children's Research Hospital

Cold Spring Harbor Laboratory

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

MD Anderson Cancer Center

Roswell Park Cancer Institute